# Thioxanthone-Mediated Cytoprotection Against Cisplatin Toxicity: Exploring the Potential Involvement of P-Glycoprotein Through Computational and Experimental Approaches

**Authors:** Jéssica Veiga-Matos, Daniel J. V. A. dos Santos, Andreia Palmeira, Emília Sousa, Ana I. Morales, Marta Prieto, Fernando Remião, Renata Silva

PMC · DOI: 10.3390/jox16020055 · 2026-03-21

## TL;DR

This study explores how thioxanthones may protect kidney cells from cisplatin toxicity by enhancing P-glycoprotein activity.

## Contribution

The study combines computational and experimental methods to investigate thioxanthone effects on P-gp in renal cells.

## Key findings

- TX2 significantly increased P-gp transport activity and expression in HK-2 cells.
- TX2 provided strong protection against cisplatin-induced cytotoxicity in kidney cells.
- Computational models identified specific binding sites for thioxanthones within P-gp.

## Abstract

P-glycoprotein (P-gp), an efflux transporter highly expressed in renal tubules, plays a crucial role in the detoxification and protection of barrier/excretory tissues from harmful xenobiotics. Xanthones and thioxanthones (TXs) are known for their antimicrobial and antitumor activities and for their ability to modulate membrane transporters such as P-gp. Previous studies have reported that (thio)xanthonic derivatives enhance P-gp expression and/or activity in intestinal cells, reducing the intracellular accumulation of toxic substrates; however, their capacity to modulate P-gp in renal cells remains poorly explored. This study aimed to predict, in silico, TXs’ binding sites within P-gp and to evaluate, in vitro, in human kidney (HK)-2 cells, the effects of selected TXs (TX1–5) on P-gp activity and expression, and protection against cisplatin-induced cytotoxicity. Computational studies identified preferential TX1–5 binding to the drug-binding pocket, particularly the rhodamine 123 (R) or modulator (M) sites, and to nucleotide-binding domain 1. In vitro, rhodamine 123 accumulation assays revealed increased P-gp transport activity after 120 min or 24 h exposure to TX1–5, except TX4. TX2 elicited the strongest effect (141% increase, p < 0.0001), upregulated P-gp expression (24 h, p < 0.0001), and significantly protected HK-2 cells from cisplatin-induced cytotoxicity (increased IC50, p < 0.0001). Altogether, these findings position thioxanthones as promising scaffolds for the development of P-gp-targeted strategies to mitigate drug-induced nephrotoxicity.

## Linked entities

- **Proteins:** Mdr65 (Multi drug resistance 65), PGP (phosphoglycolate phosphatase)
- **Chemicals:** cisplatin (PubChem CID 5460033), TX2 (PubChem CID 24833497), rhodamine 123 (PubChem CID 65217)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** NR1I2 (nuclear receptor subfamily 1 group I member 2) [NCBI Gene 8856] {aka BXR, ONR1, PAR, PAR1, PAR2, PARq}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, ATXN3 (ataxin 3) [NCBI Gene 4287] {aka AT3, ATX3, JOS, MJD, MJD1, SCA3}, Pgp (phosphoglycolate phosphatase) [NCBI Gene 67078] {aka 1700012G19Rik, AUM, G3PP}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, DBP (D-box binding PAR bZIP transcription factor) [NCBI Gene 1628] {aka DABP, taxREB302}, NR1I3 (nuclear receptor subfamily 1 group I member 3) [NCBI Gene 9970] {aka CAR, CAR1, MB67}, CD200 (CD200 molecule) [NCBI Gene 4345] {aka MOX1, MOX2, MRC, OX-2}, Pou2f2 (POU class 2 homeobox 2) [NCBI Gene 117058] {aka 2-Oct, Oct2}, ATOX1 (antioxidant 1 copper chaperone) [NCBI Gene 475] {aka ATX1, HAH1}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, Pgp (phosphoglycolate phosphatase) [NCBI Gene 287115] {aka AUM, G3PP, RGD1307773}, DNAH8 (dynein axonemal heavy chain 8) [NCBI Gene 1769] {aka ATPase, SPGF46, hdhc9}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, CASP5 (caspase 5) [NCBI Gene 838] {aka ICE(rel)III, ICEREL-III, ICH-3}, CASP4 (caspase 4) [NCBI Gene 837] {aka CASP-4, ICE(rel)II, ICEREL-II, ICH-2, Mih1, Mih1/TX}, CASP2 (caspase 2) [NCBI Gene 835] {aka CASP-2, ICH1, MRT80, NEDD-2, NEDD2, PPP1R57}, ATXN2 (ataxin 2) [NCBI Gene 6311] {aka ATX2, SCA2, TNRC13}
- **Diseases:** injury to (MESH:D014947), lung cancer (MESH:D008175), kidney toxicity (MESH:D007674), cancer (MESH:D009369), Cytotoxicity (MESH:D064420), inflammatory (MESH:D007249), MDR (MESH:D018088), mitochondrial dysfunction (MESH:D028361), osteosarcoma (MESH:D012516)
- **Chemicals:** valspodar (MESH:C070272), ARG659 (-), cardiac glycosides (MESH:D002301), digoxin (MESH:D004077), vinblastine (MESH:D014747), creatinine (MESH:D003404), streptomycin (MESH:D013307), magnesium (MESH:D008274), temsirolimus (MESH:C401859), hydrogen (MESH:D006859), calcium (MESH:D002118), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MESH:C022616), colchicine (MESH:D003078), amiodarone (MESH:D000638), Xanthones (MESH:D044004), cysteine (MESH:D003545), sirolimus (MESH:D020123), tetramethylrosamine (MESH:C412715), ethanol (MESH:D000431), DMSO (MESH:D004121), Triton  X-100 (MESH:D017830), penicillin (MESH:D010406), busulfan (MESH:D002066), tetrazolium (MESH:D013778), daunorubicin (MESH:D003630), 9H-thioxanthen-9-one (MESH:C484911), steroids (MESH:D013256), amine (MESH:D000588), ATP (MESH:D000255), NaHCO3 (MESH:D017693), omeprazole (MESH:D009853), acetic acid (MESH:D019342), dactinomycin (MESH:D003609), CO2 (MESH:D002245), formazan (MESH:D005562), verapamil (MESH:D014700), platinum (MESH:D010984), pamidronate (MESH:D000077268), CP (MESH:D002945), valproic acid (MESH:D014635), paraquat (MESH:D010269), doxorubicin (MESH:D004317), elbasvir (MESH:C000589335), nucleotide (MESH:D009711), Hoechst 33342 (MESH:C017807), QB102 (MESH:C442830), water (MESH:D014867), dibenzo-gamma-pyrone (MESH:C009689), MTT (MESH:C070243), EDTA (MESH:D004492), NR (MESH:D009499), cyclosporine A (MESH:D016572), gentamicin (MESH:D005839), RHO123 (MESH:D020112)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Cricetus cricetus (black-bellied hamster, species) [taxon 10034]
- **Mutations:** C1C, C2C
- **Cell lines:** SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), HK)-2 — Homo sapiens (Human), Transformed cell line (CVCL_0302), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), -2190 — Homo sapiens (Human), Huntington's disease, Transformed cell line (CVCL_1H58)

## Figures

32 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13010652/full.md

---
Source: https://tomesphere.com/paper/PMC13010652